– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life – The CHMP opinion is based on positive results from the Phase 3 PALISADE study where REDEMPLO reduced

April 24, 2026 -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive data from its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee at OARSI 2026 World Congress on Osteoarthritis being held in West Palm Beach, FL 23-26 April. Levicept has been selected for four presentations including a podium session in which Professor Philip Conaghan MBBS PhD, Director

Arrowhead Pharmaceuticals' therapy for familial chylomicronemia syndrome (FCS) appears to have gained a slight advantage over a competing drug from Swedish Orphan Biovitrum (Sobi) and Ionis Pharmaceuticals after an EMA panel backed approval in patients without the requirement for a genetic test. The positive opinion from the Committee for Medicinal Products for Human Use (CHMP) — disclosed on Friday — means that Arrowhead's small interfering RNA (siRNA) medicine Redemplo (plozasiran) can be use

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m AML accounts for approximately 30% of

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Medicines Agency’s human medicines committee recommended approval of the BTK inhibitor for secondary progressive multiple sclerosis (SPMS) without relapses in the past two years. The decision was based in part on data from the Phase 3 HERCULES trial, which showed tolebrutinib delayed time to onset of six

Pfizer has pulled the plug on an early-stage PD-L1 program as it looks to refine its cancer strategy after a series of encouraging readouts and high-value deals in recent months. The asset, dubbed PF-08046037, was being evaluated in a Phase 1 study, which combined the drug with sasanlimab, another investigational cancer therapy. Pfizer was testing the doublet against a variety of advanced or metastatic cancers, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and head and

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; no additional clinical studies are requested As the leader in neurotoxin development and manufacturing, AbbVie is well positioned to address all comments in a timely manner April 23, 2026 -- AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologic

Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs April 24, 2026 -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (

April 22, 2026 -- Courier Health, the leading technology company for managing patient experiences, today announced it has raised a $50 million Series B funding round led by Oak HC/FT, with participation from existing investors including Norwest and Work-Bench. This latest investment will fuel continued product innovation and solidify Courier Health's position as the leading solution to orchestrate and personalize patient journeys across the life sciences industry. Despite immense clinical innov

April 22, 2026 -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument (also known as VEL-101), a novel investigational maintenance immunosuppressive agent, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant. This follows the recent ODD granted for prevention of organ